Table 7 Influence of different... | American Society of Hematology

Table 7

Influence of different pretherapeutic parameters on EFS (only patients < 60 years)

	Cases analyzed	Univariate		Multivariate (n = 277)
	Cases analyzed	EFS P	RR	EFS P	RR
Age	339	n.s.	n.a.	-	-
Sex	339	.063	1.451	-	-
WBC*	277	< .001‡	1.006†	< .001‡	1.006
Blast count in BM	264	n.s.	n.a.	-	-
Blast count in PB	133	n.s.	n.a.	-	-
CD34⁺	189	n.s.	n.a.	-	-
FAB subtype	272	n.s.	n.a.	-	-
History	339	n.s.	n.a.	-	-
Aberrant karyotype	339	0.032	0.656	-	-.
Cytogenetic risk group*	339	< .001‡	1.988	< .001‡	1.947
IDH1*	339	.002‡	2.688	.028‡	2.166
NPM1	280	.099	1.419	-	-
FLT3-ITD	322	.080	1.472	-	-
NPM1mut + FLT3wt	339	n.s.	n.a.	-	-
FLT3-TKD	249	n.s.	n.a.	-	-
MLL-PTD	277	n.s.	n.a.	-	-
RUNX1	77	.077	1.874	-	-
CEBPA	146	n.s.	n.a.	-	-

	Cases analyzed	Univariate		Multivariate (n = 277)
	Cases analyzed	EFS P	RR	EFS P	RR
Age	339	n.s.	n.a.	-	-
Sex	339	.063	1.451	-	-
WBC*	277	< .001‡	1.006†	< .001‡	1.006
Blast count in BM	264	n.s.	n.a.	-	-
Blast count in PB	133	n.s.	n.a.	-	-
CD34⁺	189	n.s.	n.a.	-	-
FAB subtype	272	n.s.	n.a.	-	-
History	339	n.s.	n.a.	-	-
Aberrant karyotype	339	0.032	0.656	-	-.
Cytogenetic risk group*	339	< .001‡	1.988	< .001‡	1.947
IDH1*	339	.002‡	2.688	.028‡	2.166
NPM1	280	.099	1.419	-	-
FLT3-ITD	322	.080	1.472	-	-
NPM1mut + FLT3wt	339	n.s.	n.a.	-	-
FLT3-TKD	249	n.s.	n.a.	-	-
MLL-PTD	277	n.s.	n.a.	-	-
RUNX1	77	.077	1.874	-	-
CEBPA	146	n.s.	n.a.	-	-

Parameters in the univariate analysis that were included in the multivariate analysis and in the multivariate the independent significant parameters.

RR for 100-fold increase.

See Table 6.